Ascendis Pharma A/S (ASND) is a pioneering biopharmaceutical company that is dedicated to creating innovative therapies to improve people's lives. Founded in 2007, the company leverages its innovative TransCon technologies to create cutting edge, potentially life-changing treatments for rare diseases, endocrinology and oncology.
HQ is in Copenhagen, Denmark, Ascendis Pharma A/S operates on a vibrant international scale, with additional locations in the United States, Germany, and China. The company is publicly traded on the NASDAQ under the symbol ASND.
Ascendis Pharma A/S's innovative potential is reflected in its portfolio that includes an approved drug – Lonapegsomatropin (TransCon hGH), a once-weekly hormone therapy for children suffering from growth hormone deficiency. Additionally, the pipeline comprises numerous products in different phases of clinical development across multiple therapeutic areas. The company's key strength lies in its TransCon technology. This technology combines the best elements of traditional and prodrug methods to create superior therapeutics with improved safety, efficacy, and convenience.
The company's business model revolves around utilizing TransCon technology, which creates new therapies that are designed to optimize therapeutic effect, be it in rare diseases or mainstream medicine. The overarching ambitions of Ascendis Pharma A/S are driven by a deep compassion for patients and a commitment to scientific innovation. The company's experienced management team possesses extensive industry experience and a proven track record of success.
Ascendis Pharma A/S has a solid financial position, providing a strong foundation for diverse and productive R&D operations, and it looks set to build on its current successes through further expansion into unmet medical needs worldwide. In addition to their commercially available product, their impressive pipeline highlights the vast potential for growth this company promises.
Ascentis’s unwavering commitment to patient health and well-being forms the bedrock of its operations, seeking to make a tangible positive impact on patients’ lives worldwide. This company serves as a quintessential example of pioneering medical progress, facilitating cutting-edge treatments through a strategic technological approach, and demonstrating a strong commitment to improving patient outcomes. Despite its maturing profile, Ascendis Pharma A/S remains dynamic, growth-focused, and committed to building a healthier world.